On February 20, Kelso Pharma announced that it entered into an agreement to acquire Alturix Holdings for an undisclosed price.
Alturix Holdings is a pharmaceutical manufacturing company based in Milton Keynes, England. In 2020, Alturix was formed following the acquisition of two family-owned pharmaceutical businesses: HK Pharma and Atlantic Pharma.
Kelso Pharma is committed to bringing specialty medicines to the European healthcare markets. Kelso Pharma is backed by the healthcare specialist private equity investor Apposite Capital.
This is Kelso Pharma’s third acquisition and its first in 2025. In November 2023, it purchased Velit Biopharma, a biotechnology company and in January 2022, it purchased Stirling Anglian Pharmaceuticals.
This transaction also marks another step in realizing Kelso’s vision of building a specialty pharma business of scale in the United Kingdom and across Europe.
According to data in the LevinPro HC database, this transaction marks the sixth Pharmaceuticals acquisition of 2025. There were 67 Pharmaceutical transactions reported in 2024, and 107 reported in 2023.
